In the UK, as well as in many other countries, being the first to market with a generic or biosimilar to a leading branded medicine is a critical strategy that can offer a major advantage to a…
As is well known in the life sciences community in Europe, both the Commission and the Parliament have proposed reforms to the Medicines Directive which, if implemented, would serve to broaden the…
Biogen has had mixed success in Europe in enforcing its patent on a second medical use of dimethylfumarate for the treatment of multiple sclerosis. In the present Dutch case, an attempt to obtain an…
On 30 October 2024, the District Court of the Hague handed down two merits decisions on the widely litigated apixaban patent of Bristol-Myers Squibb (see here and here - Dutch language versions). EP…
On 18 September 2024, the Honourable Justice Jackman, in his capacity as a Deputy President of the Administrative Appeals Tribunal (AAT), granted Sandoz a licence pursuant to section 223(9) of the…
On 27 August 2024, the Munich Local Division awarded a preliminary injunction (‘PI’) in an action brought by Hand Held Products against Scandit for infringement of EP3866051 (“Mobile computer…
In June 2023, the UPC – at the Düsseldorf Local Division – granted its first ex parte provisional injunction (“PI”) in myStromer AG v Revolt Zycling AG (“myStromer v Revolt”), despite the defendant…
The reasons for the decision are now available in the case of Ballino v UEFA and others, following an oral hearing on 3rd of June 2004 in the Hamburg local division. As was previously known, the…
In a decision issued today, the Düsseldorf Local Division has ordered the first ever permanent injunction at the UPC following a hearing on 16 May 2024. The injunction covers seven UPC member states:…
